These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37947089)

  • 21. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.
    Toyama T; Yamashita H; Sugiura H; Kondo N; Iwase H; Fujii Y
    Jpn J Clin Oncol; 2009 Oct; 39(10):651-6. PubMed ID: 19596663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
    Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
    Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
    Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should CYP2D6 be genotyped when treating with tamoxifen?
    Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
    Pharmacogenomics; 2017 Jun; 18(8):755-756. PubMed ID: 28593824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
    Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
    Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
    Lum DW; Perel P; Hingorani AD; Holmes MV
    PLoS One; 2013; 8(10):e76648. PubMed ID: 24098545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.
    Helland T; Henne N; Bifulco E; Naume B; Borgen E; Kristensen VN; Kvaløy JT; Lash TL; Alnæs GIG; van Schaik RH; Janssen EAM; Hustad S; Lien EA; Mellgren G; Søiland H
    Breast Cancer Res; 2017 Nov; 19(1):125. PubMed ID: 29183390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
    Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
    Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
    Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
    Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.
    Hwang GS; Bhat R; Crutchley RD; Trivedi MV
    Pharmacogenomics J; 2018 Apr; 18(2):201-208. PubMed ID: 28762370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
    Brewer NT; Defrank JT; Chiu WK; Ibrahim JG; Walko CM; Rubin P; Olajide OA; Moore SG; Raab RE; Carrizosa DR; Corso SW; Schwartz G; Peppercorn JM; McLeod HL; Carey LA; Irvin WJ
    Public Health Genomics; 2014; 17(1):43-7. PubMed ID: 24457521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.
    Dezentjé VO; Guchelaar HJ; Nortier JW; van de Velde CJ; Gelderblom H
    Clin Cancer Res; 2009 Jan; 15(1):15-21. PubMed ID: 19118028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.
    Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
    Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
    Borges S; Desta Z; Li L; Skaar TC; Ward BA; Nguyen A; Jin Y; Storniolo AM; Nikoloff DM; Wu L; Hillman G; Hayes DF; Stearns V; Flockhart DA
    Clin Pharmacol Ther; 2006 Jul; 80(1):61-74. PubMed ID: 16815318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
    Dezentjé VO; Gelderblom H; Van Schaik RH; Vletter-Bogaartz JM; Van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2014 Jan; 143(1):171-9. PubMed ID: 24265036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study.
    Zhou W; Jiang Y; Xu Y; Wang Y; Ma X; Zhou L; Lin Y; Wang Y; Wu Z; Li M; Yin W; Lu J
    Int J Cancer; 2022 May; 150(10):1664-1676. PubMed ID: 34957551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
    Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
    Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.